OBJECTIVE: The role of inflammatory and endothelial dysfunction markers in the atherogenic process has been well recognized. The data have made both C-reactive protein (CRP) and von Willebrand factor (vWF) promising targets for the cardiovascular disease research and drug development. Inhibition of CRP and vWF synthesis, therefore, might be a potential therapeutic strategy. METHODS: The effect of sodium salicylate on vWF production by human umbilical vein endothelial cells (HUVECs) using enzyme-linked immunosorbent Assays (ELISA) and real-time PCR was examined. In addition, small interfering RNA (siRNA) against NF-κB was used to investigate the existence of a role for this signaling pathway. RESULTS: Our findings demonstrated that sodium salicylate decreased vWF, but not CRP production at both mRNA and protein levels significantly and this might not occur via nuclear transcription factor (NF-κB) inhibition. CONCLUSION: Our results indicated a further rationalization of the effects of sodium salicylate on atherothrombotic events by attenuation of vWF production.
OBJECTIVE: The role of inflammatory and endothelial dysfunction markers in the atherogenic process has been well recognized. The data have made both C-reactive protein (CRP) and von Willebrand factor (vWF) promising targets for the cardiovascular disease research and drug development. Inhibition of CRP and vWF synthesis, therefore, might be a potential therapeutic strategy. METHODS: The effect of sodium salicylate on vWF production by human umbilical vein endothelial cells (HUVECs) using enzyme-linked immunosorbent Assays (ELISA) and real-time PCR was examined. In addition, small interfering RNA (siRNA) against NF-κB was used to investigate the existence of a role for this signaling pathway. RESULTS: Our findings demonstrated that sodium salicylate decreased vWF, but not CRP production at both mRNA and protein levels significantly and this might not occur via nuclear transcription factor (NF-κB) inhibition. CONCLUSION: Our results indicated a further rationalization of the effects of sodium salicylate on atherothrombotic events by attenuation of vWF production.
Authors: Allen P Burke; Russell P Tracy; Frank Kolodgie; Gray T Malcom; Arthur Zieske; Robert Kutys; Joseph Pestaner; John Smialek; Renu Virmani Journal: Circulation Date: 2002-04-30 Impact factor: 29.690
Authors: Y V Sanders; J Eikenboom; E M de Wee; J G van der Bom; M H Cnossen; M E L Degenaar-Dujardin; K Fijnvandraat; P W Kamphuisen; B A P Laros-van Gorkom; K Meijer; E P Mauser-Bunschoten; F W G Leebeek Journal: J Thromb Haemost Date: 2013-05 Impact factor: 5.824
Authors: David Nanchen; David J Stott; Jacobijn Gussekloo; Simon P Mooijaart; Rudi G J Westendorp; J Wouter Jukema; Peter W Macfarlane; Jacques Cornuz; Nicolas Rodondi; Brendan M Buckley; Ian Ford; Naveed Sattar; Anton J M de Craen Journal: Eur J Heart Fail Date: 2012-12-18 Impact factor: 15.534